Intravenous frusemide for transient tachypnoea of the newborn: a randomised controlled trial.

Aim: To investigate the effect of intravenous frusemide on the course of transient tachypnoea of the newborn (TTN).

Methods: Fifty term infant with TTN were randomised at the time of diagnosis to receive either intravenous frusemide 2 mg/kg or saline placebo. Outcomes assessed included duration of supplemental oxygen requirement, the period of tachypnoea, time to discharge from hospital and weight loss in the first 24 h of life and before discharge.